

Special Issue

Emerging Biomarkers in Autoimmune Diseases: From Pharmacodynamic Insights to Therapeutic Translation

Message from the Guest Editor

This Special Issue aims to bridge the gap between emerging biomarkers in autoimmune diseases and their pharmacotherapeutic applications. We focus on leveraging biomarkers to enhance precision medicine—including guiding targeted drug selection, predicting responses to immunomodulators and biologics, monitoring pharmacodynamic (PD) effects, optimizing treatment duration, and reducing adverse drug reactions. The scope includes conditions such as rheumatoid arthritis, lupus, juvenile idiopathic arthritis, and inflammatory bowel disease, and welcomes studies integrating basic pharmacology, translational research, and clinical pharmacotherapy perspectives. We seek original research articles, reviews, and short communications on the following topics: biomarker discovery for pharmacotherapeutic stratification; validation of biomarkers for predicting drug response or toxicity; clinical application of biomarkers in guiding the use of immunomodulators and biologics; pharmacodynamic mechanisms underlying biomarker–drug correlations; and strategies to accelerate the translation of biomarkers into clinical pharmacotherapy.

Guest Editor

Dr. Kornelia Kuźnik-Trocha

Department of Clinical Chemistry and Laboratory Diagnostics, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Katowice, Poland

Deadline for manuscript submissions

25 November 2026



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/262922

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)